The JI PBL Intereron Source
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     
 

This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Smookler, D. S.
Right arrow Articles by Khokha, R.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Smookler, D. S.
Right arrow Articles by Khokha, R.
The Journal of Immunology, 2006, 176: 721-725.
Copyright © 2006 by The American Association of Immunologists

CUTTING EDGE

Cutting Edge: Tissue Inhibitor of Metalloproteinase 3 Regulates TNF-Dependent Systemic Inflammation

David S. Smookler, Fazilat F. Mohammed, Zamaneh Kassiri, Gordon S. Duncan, Tak W. Mak and Rama Khokha1

Ontario Cancer Institute, University Health Network, Toronto, Canada


   Abstract
Top
 Abstract
Introduction
 Materials and Methods
 Results and Discussion
 Disclosures
 References
 
Host response to infectious agents must be rapid and powerful. One mechanism is the release of presynthesized membrane-bound TNF. TNF shedding is mediated by TNF-{alpha} converting enzyme, which is selectively inhibited by the tissue inhibitor of metalloproteinase 3 (TIMP3). We show that loss of TIMP3 impacts innate immunity by dysregulating cleavage of TNF and its receptors. Cultured timp3–/– macrophages release more TNF in response to LPS than wild-type macrophages. In timp3–/– mice, LPS causes serum levels of TNF and its receptors to rise more rapidly and remain higher compared with wild-type mice. The altered kinetics of ligand and receptor shedding enhances TNF signaling in timp3–/– mice, indicated by elevated serum IL-6. Physiologically, timp3–/– mice are more susceptible to LPS-induced mortality. Ablation of the TNF receptor gene p55 (Tnfrsf1a) or treatment with a synthetic metalloproteinase inhibitor rescues timp3–/– mice. Thus, TIMP3 is essential for normal innate immune function.


   Introduction
Top
 Abstract
 Introduction
Materials and Methods
 Results and Discussion
 Disclosures
 References
 
More than any other cytokine TNF is central to the initiation and orchestration of inflammation. It directs circulating leukocytes to sites of infection by inducing selectin expression on endothelial cells and integrin expression on leukocytes. It promotes dendritic cell migration to lymph nodes and leukocyte migration to infected tissue via the induction of chemokine expression. It is involved in the formation of granulomas around unresolved infections. TNF also triggers clots in microvasculature, which is important for the containment of local infections and can promote cell growth, survival or death (1). Excessive or prolonged release of TNF underlies many human diseases. Although the pathophysiological importance of TNF is well illustrated by the success of anti-inflammatory therapies that rely on binding to and inactivating this cytokine (2), limitations in current therapies still remain. Understanding all aspects of TNF regulation is thus critical for developing novel therapies to control TNF activity.

TNF is expressed as a membrane-bound molecule and is released from the cell surface by proteolytic cleavage. Membrane-bound and cleaved TNF have distinct physiological effects as demonstrated in models of heart disease, arthritis, and systemic shock (3, 4, 5). Biochemically, p75/TNFRSF1B is more easily activated by membrane-bound TNF, whereas p55/TNFRSF1A readily responds to soluble TNF (5). The TNF receptors, like TNF itself, are subject to proteolytic cleavage and this process has also proved to be physiologically important. Prevention of TNFRSF1A proteolysis promotes liver inflammation and enhances sensitivity to septic shock (6). The major metalloproteinase responsible for TNF cleavage is a disintegrin and metalloprotease (ADAM) known as ADAM17 or TNF-{alpha}-converting enzyme (TACE) (7), which also cleaves both TNF receptors (8, 9). Additionally, TACE processes a number of other molecules involved in immunity and inflammation (9, 10, 11). TACE can swiftly alter the availability of TNF by cleaving it from myeloid and T cells, allowing the shed molecule to diffuse and act on the surrounding tissue, vasculature and at distant sites. Thus the regulation of TACE may be an important checkpoint for the magnitude of an inflammatory response.

Among the four tissue inhibitors of matrix metalloproteinases (TIMPs),2 TIMP3 is the only one that binds to the extracellular matrix (12) and contains an amino acid sequence (PFG) required to inhibit TACE (13). TIMP3 is induced by molecules involved in inflammation, such as the proinflammatory agent PMA and the anti-inflammatory cytokine TGF-{beta}. Aged timp3–/– mice have a normal life span in C57BL/6 and FVB strains, but develop mild lymphocytic inflammation in the liver (14). In this study we investigate the importance of TIMP3 in the pathophysiology of systemic inflammation. LPS is a strong inducer of systemic shock, it triggers TNF release (15), which mediates LPS-induced shock (16). Challenging timp3-deficient mice with LPS revealed uncontrolled systemic inflammation leading to animal morbidity due to the dysregulated TNF ligand and receptor shedding. Despite concurrent increased shedding of TNF and its receptors, the net effect was elevated TNF signaling. These data highlight the importance of TIMP3 in regulating the inflammatory response.


   Materials and Methods
Top
 Abstract
 Introduction
 Materials and Methods
Results and Discussion
 Disclosures
 References
 
Mice

Animal protocols were reviewed and approved by the animal care committee of the institute. Our previously generated timp3–/– mice were backcrossed seven times or more into the FVB/N or C57BL/6 background (17). C57BL/6-Tnfrsf1atm1Mak animals were obtained from The Jackson Laboratory.

Reagents

LPS was obtained from Sigma-Aldrich (serotype 0111:B4). Synthetic metalloproteinase inhibitor (AG3340; Pfizer) was prepared as described previously (18) and administered i.p. (2.5 mg/mouse) 90 min before LPS.

ELISAs

TNF, TNFRSF1B, and IL-6 ELISA kits were purchased from BD Pharmingen and TNFRSF1A ELISA reagents from R&D Systems.

Bone marrow-derived macrophage (BMDM) cultures

Macrophages were derived from bone marrow following a standard protocol. Briefly, cells were plated overnight to remove stromal cells and mature resident macrophages. Nonadherent cells were transferred to ultra-low attachment polystyrene plates and differentiated with 50 ng/ml M-CSF over 5 days. A total of 2.5 x 105 macrophages/well was allowed to adhere overnight and exposed to 0 or 100 ng/ml LPS for 8 h.

Quantitative real-time RT-PCR

RNA expression of timp3 was quantified by TaqMan real-time RT-PCR using an ABI Prism 7700 sequence detection system as described elsewhere (19).

Statistical analysis

Statistical differences in TNF levels were calculated using the two-tailed Student’s t test and those in serum protein levels by two-way ANOVA. The area under the curve was calculated by the trapezoid rule and survival differences using the Fisher exact test.


   Results and Discussion
Top
 Abstract
 Introduction
 Materials and Methods
 Results and Discussion
Disclosures
 References
 
Loss of timp3 significantly increases TNF shedding in primary cell culture

We investigated whether the loss of TIMP3 affects the release of TNF using in vitro and in vivo systems. Macrophages are the major source of TNF following LPS induction. We established that wild-type primary bone marrow-derived macrophages (BMDM) express TIMP3 (Fig. 1A). Macrophages obtained from timp3–/– mice in response to LPS released significantly greater levels of TNF into the medium compared with those obtained from wild-type littermates. Eight hours after LPS exposure, soluble TNF levels were 80% higher in the medium of timp3–/– macrophages (Fig. 1B, p < 0.005). This suggests that macrophages can create their own TIMP3 to regulate TNF cleavage. TIMP3 is normally anchored to the extracellular matrix by binding to chondroitin sulfate and heparin sulfate (20). Monocytes have been shown to express chondroitin sulfate and heparan sulfate (21), potentially these proteoglycans allow TIMP3 to associate directly with the macrophage cell surface. Therefore, it is possible that macrophage-generated TIMP3 acts in concert with matrix-bound TIMP3 to inhibit TNF release even more powerfully in vivo.



View larger version (15K):
[in this window]
[in a new window]
  		FIGURE 1. Cultured timp3–/– macrophages release more TNF after LPS stimulation. A, Real-time RT-PCR analysis of timp3 in BMDM relative to 18S expression indicating timp3 expression in wild-type macrophages and its lack in timp3–/– macrophages. B, Exposure of BMDM to LPS (100 ng/ml, 8 h) shows a significant increase in TNF release from timp3–/– cells ({blacksquare}) over wild-type ({square}). Values are expressed as mean ± SE of triplicate cultures (*, p < 0.005).

 
Altered shedding of TNF, TNF receptors, increased TNF signaling in timp3–/– mice

To investigate the kinetics of TNF shedding in vivo, serum was collected from LPS-treated wild-type and timp3–/– mice at 20-min intervals over 190 min after LPS injection (Fig. 2). Baseline levels of TNF were undetectable in both timp3–/– and wild-type serum. In wild-type mice, TNF levels peaked sharply at 90 min, with an attenuated peak at 150 min. In contrast, TNF levels rose more rapidly in timp3–/– mice and failed to return to the baseline levels during this time. Overall, the serum TNF levels remained elevated by ~35% over the 3-h period, as determined by the area under the curve (Fig. 2A). These data suggest that timp3 deficiency leads to accelerated TNF shedding and higher soluble TNF levels in response to LPS.



View larger version (24K):
[in this window]
[in a new window]
  		FIGURE 2. Loss of timp3 alters kinetics of serum cytokines in response to LPS. A–D, timp3+/+ and timp3–/– FVB mice were injected with 200 µg of LPS. Values represent protein levels from timed bleeds. Each mouse was tail vein bled at either 10, 30, or 50 min after LPS injection and rebled at 60-min intervals thereafter (n = 3 mice/time point). Significant differences were found between genotypes in all four panels using two-way ANOVA (p < 0.05).

 
Biochemical studies show that in addition to cleaving TNF, TACE converts membrane-bound TNF receptors to their soluble forms (9). Both TNFRs are shed in response to LPS, and TNFRSF1A (p55) release is considered essential for normal down-regulation of the inflammatory response (6). Analysis of serum from LPS-stimulated mice revealed consistently elevated levels of both TNFRs over the course of 190 min following LPS injection in timp3-deficient mice (Fig. 2, B and C). The temporal pattern of soluble TNFRSF1B mirrored that of TNFRSF1A in timp3–/– mice, showing similar dysregulation compared with wild-type mice. Thus, timp3 deficiency also affects the shedding of both TNF receptors.

Higher serum TNF increases TNF signaling, whereas greater shedding of TNF receptors can reduce TNF signaling by either binding soluble TNF or reducing the number of intact receptors available for this cytokine. Since timp3–/– mice have increased shedding of both the TNF ligand and its receptors following LPS stimulation, we sought to determine the net outcome for TNF signaling. Serum IL-6 levels were used as a measure of TNF signaling, since the rise in IL-6 in response to LPS is partially TNF dependent (22, 23). We measured the levels of IL-6 in the serum from the same timed bleed experiment. IL-6 levels were substantially increased in timp3–/– mice beginning at 70 min, with a 3-fold elevation by 150 min (Fig. 2D), demonstrating an overall increase in LPS-stimulated TNF signaling in timp3-deficient mice.

Timp3–/– mice are highly sensitive to LPS-induced septic shock

LPS is a major component of Gram-negative bacteria and is a conventional trigger for inflammation mediated by an innate immune response. TNF is a principal mediator of the lethal effects of LPS (24). We therefore investigated the physiological importance of increased TNF signaling found in the timp3–/– mice following LPS challenge. We subjected timp3 null mice and control littermates, both in the FVB background, to increasing LPS concentrations. At a sublethal dose of LPS, recovery of timp3–/– mice was significantly delayed compared with control mice (5.4 days vs 4 days, p < 0.05), as assessed by weight loss (data not shown). timp3–/– mice exposed to 200 µg of LPS showed significantly higher mortality than timp3+/– control littermates. Only 20% of the timp3–/– mice survived this dose compared with 80% or more of the control mice. This increased sensitivity to LPS was gender independent, similarly affecting male and female mice (Fig. 3, A and B). A dose of 600 µg of LPS was equally lethal for timp3 null and wild-type mice (Fig. 3C). We also compared LPS sensitivity between wild-type and timp3+/– mice and found timp3+/– mice did not significantly differ in survival (data not shown), indicating no haploinsufficiency in this model of septic shock. Thus, the loss of TIMP3 leads to pathological inflammation due to an unregulated innate immune response.



View larger version (24K):
[in this window]
[in a new window]
  		FIGURE 3. Loss of timp3 leads to reduced survival upon LPS-induced septic shock. Timp3+/– and timp3–/– FVB female (A) and male (B) mice were injected with 200 µg of LPS and monitored for signs of morbidity. The number of mice is indicated for each group. C, Females were given 600 µg of LPS. Survival was significantly higher in timp3+/– vs timp3–/– mice in A and B, p < 0.05, but not different in C.

 
Metalloproteinase inhibitor rescues LPS-mediated mortality

One study has indicated that TIMP3 can exert an effect independent of its role as a metalloproteinase inhibitor (25). We asked whether TIMP3 functioned as a metalloproteinase inhibitor to control the inflammatory response following LPS challenge. A single dose of a broad-spectrum synthetic metalloproteinase inhibitor (MPi) (AG3340) was administered to mice before LPS injection. This treatment completely rescued the timp3–/– mice from increased susceptibility to LPS, restoring the incidence of septic shock to levels found in control animals (Fig. 4A). Furthermore, the increased serum TNF levels found in untreated timp3 null animals following LPS challenge dropped to those levels observed in control animals after timp3–/– and wild-type mice were given AG3340 (Fig. 4B). These data suggest that TIMP3 functions as a metalloproteinase inhibitor during the inflammatory response.



View larger version (31K):
[in this window]
[in a new window]
  		FIGURE 4. Increased susceptibility to septic shock of timp3–/– mice is metalloproteinase and TNF-signaling dependent. A, MPi treatment rescues the increased lethality in timp3–/– mice. Experimental and control mice (FVB strain) were given MPi 90 min before LPS (200 µg) and monitored for signs of morbidity. B, Serum TNF levels at 90 min from these mice. Values are expressed relative to the control: vehicle-treated timp3+/. C, Tnfrsf1a loss rescues the increased lethality in timp3–/– mice. C and D, timp3–/– crossed with Tnfrsf1a–/–, both in the C57BL/6 background. D, TNF levels at 90 min were higher in timp3–/– mice. A–D, The sign +/ denotes a control group including wild-type and heterozygous mice of the indicated genotype. Number of mice per group is indicated. *, p < 0.05; **, p < 0.01.

 
TNFRSF1A (p55) pathway is required for heightened inflammation in timp3–/– mice

LPS-mediated septic shock is not always dependent on TNF signaling. For example, even in the absence of TNFRSF1A very high doses of LPS can cause septic shock (26). We asked whether increased susceptibility to septic shock in the absence of TIMP3 is dependent on TNF signaling, or occurs through a TNF-independent pathway. We generated double-deficient timp3–/–/Tnfrsf1a–/– mice in the C57BL/6 background. We first tested wild-type C57BL/6 for their response to LPS and found this strain to be generally more sensitive to LPS. Therefore, a lower dose of LPS (100 µg/mouse) was used for additional experiments. Ablation of Tnfrsf1a rescued the timp3–/– mice from septic shock; specifically, timp3–/–/Tnfrsf1a–/– double-knockout mice were significantly less sensitive to 100 µg of LPS compared to the timp3–/– mice (Fig. 4C). As expected, Tnfrsf1a–/– mice were completely resistant to LPS-induced shock at this dose. Furthermore, similar to the FVB mice, we found significantly higher serum TNF levels (Fig. 4D) in the timp3–/– C57BL/6 mice ({blacksquare}) than those in their controls ({square}), taken 90 min after LPS injection. It has been previously reported that in response to LPS, serum TNF levels are significantly higher in Tnfrsf1a null mice compared to wild-type controls (27), suggesting this receptor is involved in lowering serum TNF levels. We also found that soluble TNF levels in the timp3–/–/Tnfrsf1a–/–double-deficient mice were significantly higher than those in controls (Fig. 4D, black striped bars vs open bar). IL-6 levels for both timp3+/ and timp3–/– groups dropped when combined with Tnfrsf1a loss, 30% in timp3+/ mice (p = 0.089) and 43% in timp3–/– mice (p = 0.024). These data show that an intact TNF signaling pathway is necessary for the heightened LPS-induced inflammatory response in the timp3–/– mice.

Inflammation is necessarily a rapid and powerful response that is essential for host survival yet has the potential for devastating consequences if not precisely controlled. timp3-deficient mice not only exhibit accelerated TNF shedding into serum, but the release of TNF receptors is also enhanced. Dysregulation of the TNF system results in a net increase in TNF signaling, reflected in IL-6 levels, leading to heightened septic shock and animal mortality. Thus, TIMP3 is a critical regulator of the release of presynthesized, membrane-bound mediators, dictating the magnitude of the inflammatory response. The source of TIMP3 regulating these events, stromal and/or hemopoietic, is an important question that remains to be investigated.

The innate immune system is an ancient response to infection, some elements of which are shared by all multicellular species (28). The TIMPs are also an ancient family of genes, strongly conserved throughout evolution (29). The loss of TIMP in Drosophila leads to autolysis and premature death in the adult fly (30). The Drosophila TIMP can inhibit human TACE; it is functionally and structurally most similar to TIMP3 (29). TIMP3 is unique among the mammalian TIMPs in its ability to inhibit TACE, the enzyme primarily responsible for releasing TNF (7, 31). In this capacity TIMP3 is ideally situated to protect the organism against an overactive innate immune response by inhibiting the wide release of a powerful initiator of inflammation. Our study was designed to understand an extracellular point of control in acute systemic inflammation, specifically focusing on TNF signaling, which plays a principal role in initiating inflammation. TNF regulation has become a focus for a new generation of anti-inflammatory therapies and we postulate that TIMP3-based therapies can be developed to control inflammation.


   Disclosures
Top
 Abstract
 Introduction
 Materials and Methods
 Results and Discussion
 Disclosures
References
 
The authors have no financial conflict of interest.


   Footnotes
 
The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

1 Address correspondence and reprint requests to Dr. Rama Khokha, Ontario Cancer Institute, 610 University Avenue, Toronto, Ontario, Canada, M5G 2M9. E-mail address: rkhokha{at}uhnres.utoronto.ca Back

2 Abbreviations used in this paper: TIMP, tissue inhibitor of metalloproteinase; BMDM, bone marrow-derived macrophage; TACE, TNF-{alpha}-converting enzyme; MPi, synthetic metalloproteinase inhibitor. Back

Received for publication August 2, 2005. Accepted for publication November 1, 2005.


   References
Top
 Abstract
 Introduction
 Materials and Methods
 Results and Discussion
 Disclosures
 References
 

  1. Baker, S. J., E. P. Reddy. 1998. Modulation of life and death by the TNF receptor superfamily. Oncogene 17: 3261-3270. [Medline]
  2. Reimold, A. M.. 2002. TNF{alpha} as therapeutic target: new drugs, more applications. Curr. Drug Targets Inflamm. Allergy 1: 377-392. [Medline]
  3. Diwan, A., Z. Dibbs, S. Nemoto, G. DeFreitas, B. A. Carabello, N. Sivasubramanian, E. M. Wilson, F. G. Spinale, D. L. Mann. 2004. Targeted overexpression of noncleavable and secreted forms of tumor necrosis factor provokes disparate cardiac phenotypes. Circulation 109: 262-268. [Medline]
  4. Georgopoulos, S., D. Plows, G. Kollias. 1996. Transmembrane TNF is sufficient to induce localized tissue toxicity and chronic inflammatory arthritis in transgenic mice. J. Inflamm. 46: 86-97. [Medline]
  5. Ruuls, S. R., R. M. Hoek, V. N. Ngo, T. McNeil, L. A. Lucian, M. J. Janatpour, H. Korner, H. Scheerens, E. M. Hessel, J. G. Cyster, et al 2001. Membrane-bound TNF supports secondary lymphoid organ structure but is subservient to secreted TNF in driving autoimmune inflammation. Immunity 15: 533-543. [Medline]
  6. Xanthoulea, S., M. Pasparakis, S. Kousteni, C. Brakebusch, D. Wallach, J. Bauer, H. Lassmann, G. Kollias. 2004. Tumor necrosis factor (TNF) receptor shedding controls thresholds of innate immune activation that balance opposing TNF functions in infectious and inflammatory diseases. J. Exp. Med. 200: 367-376. [Abstract/Free Full Text]
  7. Black, R. A., C. T. Rauch, C. J. Kozlosky, J. J. Peschon, J. L. Slack, M. F. Wolfson, B. J. Castner, K. L. Stocking, P. Reddy, S. Srinivasan, et al 1997. A metalloproteinase disintegrin that releases tumour-necrosis factor-{alpha} from cells. Nature 385: 729-733. [Medline]
  8. Peschon, J. J., J. L. Slack, P. Reddy, K. L. Stocking, S. W. Sunnarborg, D. C. Lee, W. E. Russell, B. J. Castner, R. S. Johnson, J. N. Fitzner, et al 1998. An essential role for ectodomain shedding in mammalian development. Science 282: 1281-1284. [Abstract/Free Full Text]
  9. Reddy, P., J. L. Slack, R. Davis, D. P. Cerretti, C. J. Kozlosky, R. A. Blanton, D. Shows, J. J. Peschon, R. A. Black. 2000. Functional analysis of the domain structure of tumor necrosis factor-{alpha} converting enzyme. J. Biol. Chem. 275: 14608-14614. [Abstract/Free Full Text]
  10. Borland, G., G. Murphy, A. Ager. 1999. Tissue inhibitor of metalloproteinases-3 inhibits shedding of L-selectin from leukocytes. J. Biol. Chem. 274: 2810-2815. [Abstract/Free Full Text]
  11. Garton, K. J., P. J. Gough, C. P. Blobel, G. Murphy, D. R. Greaves, P. J. Dempsey, E. W. Raines. 2001. Tumor necrosis factor-{alpha}-converting enzyme (ADAM17) mediates the cleavage and shedding of fractalkine (CX3CL1). J. Biol. Chem. 276: 37993-38001. [Abstract/Free Full Text]
  12. Mohammed, F. F., D. S. Smookler, R. Khokha. 2003. Metalloproteinases, inflammation, and rheumatoid arthritis. Ann. Rheum. Dis. 62: (Suppl. 2):ii43-ii47. [Abstract/Free Full Text]
  13. Lee, M. H., M. Rapti, G. Murphy. 2005. Total conversion of tissue inhibitor of metalloproteinase (TIMP) for specific metalloproteinase targeting: fine-tuning TIMP-4 for optimal inhibition of tumor necrosis factor-{alpha}-converting enzyme. J. Biol. Chem. 280: 15967-15975. [Abstract/Free Full Text]
  14. Mohammed, F. F., D. S. Smookler, S. E. Taylor, B. Fingleton, Z. Kassiri, O. H. Sanchez, J. L. English, L. M. Matrisian, B. Au, W. C. Yeh, R. Khokha. 2004. Abnormal TNF activity in timp3–/– mice leads to chronic hepatic inflammation and failure of liver regeneration. Nat. Genet. 36: 969-977. [Medline]
  15. Carswell, E. A., L. J. Old, R. L. Kassel, S. Green, N. Fiore, B. Williamson. 1975. An endotoxin-induced serum factor that causes necrosis of tumors. Proc. Natl. Acad. Sci. USA 72: 3666-3670. [Abstract/Free Full Text]
  16. Pfeffer, K., T. Matsuyama, T. M. Kundig, A. Wakeham, K. Kishihara, A. Shahinian, K. Wiegmann, P. S. Ohashi, M. Kronke, T. W. Mak. 1993. Mice deficient for the 55 kD tumor necrosis factor receptor are resistant to endotoxic shock, yet succumb to L. monocytogenes infection. Cell 73: 457-467. [Medline]
  17. Leco, K. J., P. Waterhouse, O. H. Sanchez, K. L. Gowing, A. R. Poole, A. Wakeham, T. W. Mak, R. Khokha. 2001. Spontaneous air space enlargement in the lungs of mice lacking tissue inhibitor of metalloproteinases-3 (TIMP-3). J. Clin. Invest. 108: 817-829. [Medline]
  18. Price, A., Q. Shi, D. Morris, M. E. Wilcox, P. M. Brasher, N. B. Rewcastle, D. Shalinsky, H. Zou, K. Appelt, R. N. Johnston, et al 1999. Marked inhibition of tumor growth in a malignant glioma tumor model by a novel synthetic matrix metalloproteinase inhibitor AG3340. Clin. Cancer Res. 5: 845-854. [Abstract/Free Full Text]
  19. Kassiri, Z., G. Y. Oudit, O. Sanchez, F. Dawood, F. F. Mohammed, R. K. Nuttall, D. R. Edwards, P. P. Liu, P. H. Backx, R. Khokha. 2005. Combination of TNF{alpha} ablation and MMP inhibition prevents heart failure after pressure overload in TIMP-3 mutant mice. Circ. Res. 97: 380-390. [Abstract/Free Full Text]
  20. Yu, W. H., S. Yu, Q. Meng, K. Brew, J. F. Woessner, Jr. 2000. TIMP-3 binds to sulfated glycosaminoglycans of the extracellular matrix. J. Biol. Chem. 275: 31226-31232. [Abstract/Free Full Text]
  21. Levitt, D., P. L. Ho. 1983. Induction of chondroitin sulfate proteoglycan synthesis and secretion in lymphocytes and monocytes. J. Cell Biol. 97: 351-358. [Abstract/Free Full Text]
  22. Engelberts, I., E. J. von Asmuth, C. J. van der Linden, W. A. Buurman. 1991. The interrelation between TNF, IL-6, and PAF secretion induced by LPS in an in vivo and in vitro murine model. Lymphokine Cytokine Res. 10: 127-131. [Medline]
  23. Ghezzi, P., S. Sacco, D. Agnello, A. Marullo, G. Caselli, R. Bertini. 2000. Lps induces IL-6 in the brain and in serum largely through TNF production. Cytokine 12: 1205-1210. [Medline]
  24. Beutler, B., I. W. Milsark, A. C. Cerami. 1985. Passive immunization against cachectin/tumor necrosis factor protects mice from lethal effect of endotoxin. Science 229: 869-871. [Abstract/Free Full Text]
  25. Qi, J. H., Q. Ebrahem, N. Moore, G. Murphy, L. Claesson-Welsh, M. Bond, A. Baker, B. Anand-Apte. 2003. A novel function for tissue inhibitor of metalloproteinases-3 (TIMP3): inhibition of angiogenesis by blockage of VEGF binding to VEGF receptor-2. Nat. Med. 9: 407-415. [Medline]
  26. Rothe, J., W. Lesslauer, H. Lotscher, Y. Lang, P. Koebel, F. Kontgen, A. Althage, R. Zinkernagel, M. Steinmetz, H. Bluethmann. 1993. Mice lacking the tumour necrosis factor receptor 1 are resistant to TNF-mediated toxicity but highly susceptible to infection by Listeria monocytogenes. Nature 364: 798-802. [Medline]
  27. Peschon, J. J., D. S. Torrance, K. L. Stocking, M. B. Glaccum, C. Otten, C. R. Willis, K. Charrier, P. J. Morrissey, C. B. Ware, K. M. Mohler. 1998. TNF receptor-deficient mice reveal divergent roles for p55 and p75 in several models of inflammation. J. Immunol. 160: 943-952. [Abstract/Free Full Text]
  28. Beutler, B., A. Poltorak. 2001. Sepsis and evolution of the innate immune response. Crit. Care Med. 29: S2-S6. [Medline]
  29. Wei, S., Z. Xie, E. Filenova, K. Brew. 2003. Drosophila TIMP is a potent inhibitor of MMPs and TACE: similarities in structure and function to TIMP-3. Biochemistry 42: 12200-12207. [Medline]
  30. Godenschwege, T. A., N. Pohar, S. Buchner, E. Buchner. 2000. Inflated wings, tissue autolysis and early death in tissue inhibitor of metalloproteinases mutants of Drosophila. Eur. J. Cell Biol. 79: 495-501. [Medline]
  31. Parks, W. C., C. L. Wilson, Y. S. Lopez-Boado. 2004. Matrix metalloproteinases as modulators of inflammation and innate immunity. Nat. Rev. Immunol. 4: 617-629. [Medline]



This article has been cited by other articles:


Home page
 Proc. Natl. Acad. Sci. USAHome page
S. Alper, R. Laws, B. Lackford, W. A. Boyd, P. Dunlap, J. H. Freedman, and D. A. Schwartz
Identification of innate immunity genes and pathways using a comparative genomics approach
PNAS, May 13, 2008; 105(19): 7016 - 7021.
[Abstract] [Full Text] [PDF]

Home page
 Nephrol Dial TransplantHome page
G. Cai, X. Zhang, Q. Hong, F. Shao, X. Shang, B. Fu, Z. Feng, H. Lin, J. Wang, S. Shi, et al.
Tissue inhibitor of metalloproteinase-1 exacerbated renal interstitial fibrosis through enhancing inflammation
Nephrol. Dial. Transplant., March 8, 2008; (2008) gfm666v1.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
N. Ali and V. Knauper
Phorbol Ester-induced Shedding of the Prostate Cancer Marker Transmembrane Protein with Epidermal Growth Factor and Two Follistatin Motifs 2 Is Mediated by the Disintegrin and Metalloproteinase-17
J. Biol. Chem., December 28, 2007; 282(52): 37378 - 37388.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Respir. Crit. Care Med.Home page
N. Pottier, C. Chupin, V. Defamie, B. Cardinaud, R. Sutherland, G. Rios, F. Gauthier, P. J. Wolters, Y. Berthiaume, P. Barbry, et al.
Relationships between Early Inflammatory Response to Bleomycin and Sensitivity to Lung Fibrosis: A Role for Dipeptidyl-Peptidase I and Tissue Inhibitor of Metalloproteinase-3?
Am. J. Respir. Crit. Care Med., December 1, 2007; 176(11): 1098 - 1107.
[Abstract] [Full Text] [PDF]

Home page
 DiabetesHome page
M. Serino, R. Menghini, L. Fiorentino, R. Amoruso, A. Mauriello, D. Lauro, P. Sbraccia, M. L. Hribal, R. Lauro, and M. Federici
Mice Heterozygous for Tumor Necrosis Factor-{alpha} Converting Enzyme Are Protected From Obesity-Induced Insulin Resistance and Diabetes
Diabetes, October 1, 2007; 56(10): 2541 - 2546.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
K. Horiuchi, T. Kimura, T. Miyamoto, H. Takaishi, Y. Okada, Y. Toyama, and C. P. Blobel
Cutting Edge: TNF-{alpha}-Converting Enzyme (TACE/ADAM17) Inactivation in Mouse Myeloid Cells Prevents Lethality from Endotoxin Shock
J. Immunol., September 1, 2007; 179(5): 2686 - 2689.
[Abstract] [Full Text] [PDF]

This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Smookler, D. S.
Right arrow Articles by Khokha, R.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Smookler, D. S.
Right arrow Articles by Khokha, R.

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS